A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation

Clinical trial NCT04285567 · COMPLETED

Trial details

NCT number: NCT04285567
Sponsor: Hoffmann-La Roche
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Chronic Lymphocytic Leukemia (CLL)

Start date: 2020-05-28
Primary completion: 2024-03-19
Enrollment: 166

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.